Behavioral and cortical EEG evaluations confirm the roles of both CCKA and CCKB receptors in mouse CCK-induced anxiety

Behavioural Brain Research

Volumn 237, Issue 1, 2013, Pages 325-332

  Li, Heng ^a   Ohta, Hidenobu ^a   Izumi, Hitomi ^a   Matsuda, Yoshiki ^a   Seki, Mika ^a   Toda, Takako ^a   Akiyama, Misaki ^a   Matsushima, Yukiko ^a   Goto, Yu Ichi ^b   Kaga, Makiko ^a   Inagaki, Masumi ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

BMP; Brain CCKA and CCKB receptors; C Fos immunopositive neurons; CCK; CCK 4; CG; EEG monitoring; FFT; I.c.v.; Mouse anxiety tests

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; DEVAZEPIDE; PROTEIN C FOS; TETRAGASTRIN;

AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; BEHAVIOR CHANGE; BRAIN CORTEX; CONTROLLED STUDY; ELECTROCORTICOGRAPHY; IMMUNOHISTOCHEMISTRY; LIGHT DARK CYCLE; MAZE TEST; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BLOCKING;

ADAPTATION, PHYSIOLOGICAL; ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN; BRAIN MAPPING; BRAIN WAVES; DEVAZEPIDE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; GENE EXPRESSION REGULATION; INDOLES; INJECTIONS, INTRAVENTRICULAR; MALE; MAZE LEARNING; MEGLUMINE; MICE; MICE, INBRED C57BL; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; SPECTRUM ANALYSIS; TETRAGASTRIN;

EID: 84867652840     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.09.051     Document Type: Article

References (40)

1. Bradwejn J., Koszycki D., Meterissian G. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 1990, 35:83-85.
2. Bradwejn J. Neurobiological investigations into the role of cholecystokinin in panic disorder. Journal of Psychiatric Nursing and Mental Health Services 1993, 18:178-188.
3. Bradwejn J., Koszycki D. The cholecystokinin hypothesis of anxiety and panic disorder. Annals of the New York Academy of Sciences 1994, 713:273-282.
4. Bourin M., Malinge M., Vasar E., Bradwejn J. Two faces of cholecystokinin: anxiety and schizophrenia. Fundamental and Clinical Pharmacology 1996, 10:116-126.
5. Beinfeld M.C., Garver D.L. Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1991, 15:601-609.
6. Ferrier I.N., Roberts G.W., Crow T.J., Johnstone E.C., Owens D.G., Lee Y.C., et al. Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia. Life Sciences 1983, 33:475-482.
7. Garver D.L., Beinfeld M.C., Yao J.K. Cholecystokinin, dopamine and schizophrenia. Psychopharmacology Bulletin 1990, 26:377-380.
8. Nair N.P., Lal S., Bloom D.M. Cholecystokinin peptides, dopamine and schizophrenia-a review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1985, 9:515-524.
9. Wang R.Y. Cholecystokinin, dopamine, and schizophrenia: recent progress and current problems. Annals of the New York Academy of Sciences 1988, 537:362-379.
10. Vaccarino F.J., Rankin J. Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function. Behavioral Neuroscience 1989, 103:831-836.
11. Higgins G.A., Sills T.L., Tomkins D.M., Sellers E.M., Vaccarino F.J. Evidence for the contribution of CCKB receptor mechanisms to individual differences in amphetamine-induced locomotion. Pharmacology Biochemistry and Behavior 1994, 48:1019-1024.
12. Crespi F. The role of cholecystokinin (CCK), CCK-A or CCK-B receptor antagonists in the spontaneous preference for drugs of abuse (alcohol or cocaine) in naive rats. Methods and Findings in Experimental and Clinical Pharmacology 1998, 20:679-697.
13. Crespi F., Corsi M., Reggiani A., Ratti E., Gaviraghi G. Involvement of cholecystokinin within craving for cocaine: role of cholecystokinin receptor ligands. Expert Opinion on Investigational Drugs 2000, 9:2249-2258.
14. Vaccarino F.C.C.K. addiction and anxiety. Cholecystokinin and anxiety: from neuron to behavior 1995, 127-142. RG Landes Company, Austin (TX). J. Bradwejn, E. Vasar (Eds.).
15. Wunderlich G.R., DeSousa N.J., Vaccarino F.J. Cholecystokinin modulates both the development and the expression of behavioral sensitization to amphetamine in the rat. Psychopharmacology (Berlin) 2000, 151:283-290.
16. Ivy A., Oldberg E. A hormone mechanism for gallbladder contraction and evacuation. American Journal of Physiology 1928, 86:599-613.
17. Dockray G.J. Immunochemical evidence of cholecystokinin-like peptides in brain. Nature 1976, 264:568-570.
18. Rehfeld J.F. Immunochemical studies on cholecystokinin. I. Development of sequence-specific radioimmunoassays for porcine triacontatriapeptide cholecystokinin. Journal of Biological Chemistry 1978, 253:4016-4021.
19. Lorén I., Alumets J., Håkanson R., Sundler F. Distribution of gastrin and CCK-like peptides in rat brain. An immunocytochemical study. Histochemistry 1979, 59:249-257.
20. Hökfelt T., Cortés R., Schalling M., Ceccatelli S., Pelto-Huikko M., Persson H., et al. Distribution patterns of CCK and CCK mRNA in some neuronal and non-neuronal tissues. Neuropeptides 1991, 19(Suppl.):31-43.
21. Patel M., Spraggs C.F. Functional comparisons of gastrin/cholecystokinin receptors in isolated preparations of gastric mucosa and ileum. British Journal of Pharmacology 1992, 106:275-282.
22. Hill D.R., Woodruff G.N. Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365, 260. Brain Research 1990, 526:276-283.
23. Wank S.A. Cholecystokinin receptors. American Journal of Physiology 1995, 269:G628-G646.
24. Latorre M., Bartolomé-Nebreda J.M., García-López M.T., González-Muñiz R., Herranz R., Del Río J., et al. Pharmacological study of IQM-97,423, a potent and selective CCK1 receptor antagonist with protective effect in experimental acute pancreatitis. Pharmacology 2004, 72:68-76.
25. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D.C., et al. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:6728-6732.
26. Hendrie C.A., Neill J.C., Shepherd J.K., Dourish C.T. The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice. Physiology and Behavior 1993, 54:689-693.
27. Rotzinger S., Vaccarino F.J. Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models. Journal of Psychiatry and Neuroscience 2003, 28:171-181.
28. Shlik J., Vasar E., Bradwejn J. Cholecystokinin and psychiatric disorders: role in aethiology and potential of receptor antagonists in therapy. CNS Drugs 1997, 8:134-152.
29. Csonka E., Fekete M., Magy G., Szanto-Fekete M., Feledgy G., Penke B., et al. Anxiogenic effect of cholecystokinin in rats. Peptides 1988, 249-252. Walter de Gruyter and Co., New York. B. Penke, A. Torok (Eds.).
30. Palmour R., Bradwejn J., Ervin F. The anxiogenic effects of CCK-4 in monkeys are reduced by CCK B antagonists, benzodiazepines or adenosine A2 agonists. European Neuropsychopharmacology 1992, 2:193-195.
31. Harro J., Vassar E., Koszycki D., Bradwejn J. Cholecystokinin in panic and anxiety disorders. Advances in Biological Psychiatry 1985, 1:235-262.
32. Pérez de la Mora M., Hernández-Gómez A.M., Arizmendi-García Y., Jacobsen K.X., Lara-García D., Flores-Gracia C., et al. Role of the amygdaloid cholecystokinin (CCK)/gastrin-2 receptors and terminal networks in the modulation of anxiety in the rat. Effects of CCK-4 and CCK-8S on anxiety-like behaviour and [3H]GABA release. European Journal of Neuroscience 2007, 26:3614-3630.
33. Daugé V., Steimes P., Derrien M., Beau N., Roques B.P., Féger J. CCK8 effects on motivational and emotional states of rats involve CCKA receptors of the postero-median part of the nucleus accumbens. Pharmacology Biochemistry and Behavior 1989, 34:157-163.
34. Singh L., Lewis A.S., Field M.J., Hughes J., Woodruff G.N. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:1130-1133.
35. Gorman J.M., Kent J.M., Sullivan G.M., Coplan J.D. Neuroanatomical hypothesis of panic disorder, revised. American Journal of Psychiatry 2000, 157:493-505.
36. Adhikari A., Topiwala M.A., Gordon J.A. Synchronized activity between the ventral hippocampus and the medial prefrontal cortex during anxiety. Neuron 2010, 65:257-269.
37. Kim S.S., Wang H., Li X.Y., Chen T., Mercaldo V., Descalzi G., et al. Neurabin in the anterior cingulate cortex regulates anxiety-like behavior in adult mice. Molecular Brain 2011, 4:6.
38. Lombroso C.T. Neonatal seizures: gaps between the laboratory and the clinic. Epilepsia 2007, 48(Suppl. 2):83-106.
39. Narayanan V., Heiming R.S., Jansen F., Lesting J., Sachser N., Pape H.C., et al. Social defeat: impact on fear extinction and amygdala-prefrontal cortical theta synchrony in 5-HTT deficient mice. PLoS One 2011, 6:e22600.
40. Likhtik E., Pelletier J.G., Paz R., Paré D. Prefrontal control of the amygdala. Journal of Neuroscience 2005, 25:7429-7437.